-
Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering
-
Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial
-
Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission
-
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
-
Zelluna ASA – Grant of Share Options
-
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
-
Zelluna promotes Emilie Gauthy to Chief Technology Officer
-
Zelluna ASA: Approval and publication of prospectus
-
Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours
-
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World’s First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
